Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients

被引:29
|
作者
Hodel, Eva Maria Staehli [1 ]
Guidi, Monia [2 ,3 ,4 ]
Zanolari, Boris [3 ,4 ]
Mercier, Thomas [3 ,4 ]
Duong, Socheat [5 ]
Kabanywanyi, Abdunoor M. [6 ]
Ariey, Frederic [7 ]
Buclin, Thierry [3 ,4 ]
Beck, Hans-Peter [1 ]
Decosterd, Laurent A. [3 ,4 ]
Olliaro, Piero [8 ]
Genton, Blaise [1 ,9 ,10 ]
Csajka, Chantal [2 ,3 ,4 ]
机构
[1] Univ Basel, Swiss Trop & Publ Hlth Inst, Basel, Switzerland
[2] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
[3] CHU Vaudois, Dept Labs, Div Clin Pharmacol & Toxicol, CH-1011 Lausanne, Switzerland
[4] Univ Lausanne, Lausanne, Switzerland
[5] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia
[6] Ifakara Hlth Inst, Dar Es Salaam, Tanzania
[7] Inst Pasteur Cambodia, Mol Epidemiol Unit, Phnom Penh, Cambodia
[8] UNICEF UNDP World Bank WHO Special Programme Res, Geneva, Switzerland
[9] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland
[10] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
Malaria; Population pharmacokinetics; Artemisinin-based combination therapy; Tanzania; Cambodia; Piperaquine; Mefloquine; Lumefantrine; Artemether; Nonlinear mixed-effects modelling; PLASMODIUM-FALCIPARUM MALARIA; SINGLE NUCLEOTIDE POLYMORPHISMS; ARTEMISININ-RESISTANT MALARIA; SULFADOXINE-PYRIMETHAMINE; UNCOMPLICATED MALARIA; COMBINATION TREATMENT; PLASMA-CONCENTRATIONS; THERAPEUTIC RESPONSE; PREGNANT-WOMEN; ANTIMALARIAL;
D O I
10.1186/1475-2875-12-235
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Inter-individual variability in plasma concentration-time profiles might contribute to differences in anti-malarial treatment response. This study investigated the pharmacokinetics of three different forms of artemisinin combination therapy (ACT) in Tanzania and Cambodia to quantify and identify potential sources of variability. Methods: Drug concentrations were measured in 143 patients in Tanzania (artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine), and in 63 (artesunate, dihydroartemisinin and mefloquine) and 60 (dihydroartemisinin and piperaquine) patients in Cambodia. Inter-and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM (R)). Results: A one-compartment model with first-order absorption from the gastrointestinal tract fitted the data for all drugs except piperaquine (two-compartment). Inter-individual variability in concentration exposure was about 40% and 12% for mefloquine. From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs' pharmacokinetic profiles. Artesunate and dihydroartemisinin could not be studied in the Cambodian patients due to insufficient data-points. Modeled lumefantrine kinetics showed that the target day 7 concentrations may not be achieved in a substantial proportion of patients. Conclusion: The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates. Dosing on body weight appears justified. The concomitance of unregulated drug use (residual levels found on admission) and sub-optimal exposure (variability) could generate low plasma levels that contribute to selecting for drug-resistant parasites.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] EFFICACY OF ARTEMETHER-LUMEFANTRINE AND DIHYDROARTEMISININ-PIPERAQUINE FOR THE TREATMENT OF UNCOMPLICATED <it>PLASMODIUM FALCIPARUM</it> MALARIA AMONG CHILDREN IN WESTERN KENYA
    Westercamp, Nelli
    Owidhi, Mary
    Otieno, Kephas
    Chebore, Winnie
    Buff, Ann
    Desai, Meghna
    Kariuki, Simon
    Samuels, Aaron
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 312 - 312
  • [42] Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial
    Bassat, Quique
    Mulenga, Modest
    Tinto, Halidou
    Piola, Patrice
    Borrmann, Steffen
    Menendez, Clara
    Nambozi, Michael
    Valea, Innocent
    Nabasumba, Carolyn
    Sasi, Philip
    Bacchieri, Antonella
    Corsi, Marco
    Ubben, David
    Talisuna, Ambrose
    D'Alessandro, Umberto
    PLOS ONE, 2009, 4 (11):
  • [43] THE EFFECT OF ARTEMETHER-LUMEFANTRINE ON GAMETOCYTE CARRIAGE IN PLASMODIUM FALCIPARUM MALARIA
    Premji, Zulfiqarali
    Bassat, Quique
    Djimde, Abdoulaye A.
    Falade, Catherine O.
    Gonzalez, Raquel
    Cousin, Marc
    Hunt, Philip
    Oladiran, Fiyinfolu
    Walter, Verena
    Ogutu, Bernhards
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 88 - 88
  • [44] ARTEMETHER-LUMEFANTRINE VERSUS DIHYDROARTEMISININ-PIPERAQUINE FOR THE TREATMENT OF UNCOMPLICATED MALARIA: A RANDOMIZED LONGITUDINAL TRIAL IN A COHORT OF UGANDAN INFANTS
    Arinaitwe, Emmanuel
    Sandison, Taylor
    Homsy, Jaco
    Kalamya, Julius
    Kakuru, Abel
    Wanzira, Humphrey
    Vora, Neil
    Rosenthal, Philip J.
    Kamya, Moses
    Tappero, Jordan W.
    Dorsey, Grant
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 215 - 215
  • [45] Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
    Katrak, Shereen
    Gasasira, Anne
    Arinaitwe, Emmanuel
    Kakuru, Abel
    Wanzira, Humphrey
    Bigira, Victor
    Sandison, Taylor G.
    Homsy, Jaco
    Tappero, Jordan W.
    Kamya, Moses R.
    Dorsey, Grant
    MALARIA JOURNAL, 2009, 8
  • [46] Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine in combination treatment of uncomplicated falciparum malaria in pediatric patients
    Hietala, S. Friberg
    Martensson, A.
    Ngasala, B.
    Dahlstrom, S.
    Lindegardh, N.
    Annerberg, A.
    Premji, Z.
    Farnert, A.
    Gil, P.
    Bjorkman, A.
    Ashton, M.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2009, 14 : 130 - 131
  • [47] The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine
    Djimde, Abdoulaye A.
    Makanga, Michael
    Kuhen, Kelli
    Hamed, Kamal
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (08) : 1031 - 1045
  • [48] Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria
    van Vugt, M
    Looareesuwan, S
    Wilairatana, P
    McGready, R
    Villegas, L
    Gathmann, I
    Mull, R
    Brockman, A
    White, NJ
    Nosten, F
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2000, 94 (05) : 545 - 548
  • [49] Adherence to Treatment With Artemether-Lumefantrine for Uncomplicated Malaria in Rural Malawi
    Mace, Kimberly E.
    Mwandama, Dyson
    Jafali, James
    Luka, Madalitso
    Filler, Scott J.
    Sande, John
    Ali, Doreen
    Kachur, S. Patrick
    Mathanga, Don P.
    Skarbinski, Jacek
    CLINICAL INFECTIOUS DISEASES, 2011, 53 (08) : 772 - 779
  • [50] Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
    Michael Nambozi
    Jean-Pierre Van Geertruyden
    Sebastian Hachizovu
    Mike Chaponda
    Doreen Mukwamataba
    Modest Mulenga
    David Ubben
    Umberto D'Alessandro
    Malaria Journal, 10